Me is to cut 200 jobs in the wake of declining revenues. This company expects a proposed retructuring, affecting 40% of its ...
The DNA-testing firm said in a Tuesday SEC filing, “there is substantial doubt about the company’s ability to continue.” ...
Genetic testing company 23andMe has faced a series of struggles this year, culminating in end-of-year mass layoffs — 40% of ...
But it’s not just staffing changes: 23andMe is also shutting down its entire therapeutics division, which had been working ...
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies ...
The DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on ...
Though 23andMe says the restructuring plan will cost it around $12 million, it expects to save more than $35 million as a ...
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to ...
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
Anne Wojcicki; Chairman of the Board, President, Chief Executive Officer, Co-Founder; 23andMe Holding Co. Joseph Selsavage; Interim Chief Financial Officer, Chief Accounting Officer; 23andMe ...